BRCA2 and neoplasm: Among the 14 patients recruited for the gene expression study by real-time PCR, all 4 patients (28.57%) of stage IV HNSCC (AU/SMC/CA-1, AU/SMC/CA-6, AU/SMC/CA-27 and AU/SMS/CA-44; Figure 3) exhibited low levels of expression of the BRCA2 gene in matched tumour and blood samples, concomitant with low levels of the BRCA2 protein in the PBL.